Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance.

Camgoz A, Gencer EB, Ural AU, Baran Y.

Leuk Lymphoma. 2013 Jun;54(6):1279-87. doi: 10.3109/10428194.2012.737919. Epub 2012 Nov 20.

PMID:
23098068
2.

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW.

Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865 . Review.

PMID:
18491988
3.

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.

Erba HP, Pham DC, Zaiden R, Vu H, Tai S.

Clin Adv Hematol Oncol. 2011 Oct;9(10):734-45. Review.

PMID:
22252576
4.

Important therapeutic targets in chronic myelogenous leukemia.

Kantarjian HM, Giles F, Quintás-Cardama A, Cortes J.

Clin Cancer Res. 2007 Feb 15;13(4):1089-97. Review.

5.

Overcoming kinase resistance in chronic myeloid leukemia.

Lee F, Fandi A, Voi M.

Int J Biochem Cell Biol. 2008;40(3):334-43. Review.

PMID:
18401881
6.

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).

Walz C, Sattler M.

Crit Rev Oncol Hematol. 2006 Feb;57(2):145-64. Epub 2005 Oct 5. Review.

PMID:
16213151
7.

The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.

Hantschel O, Grebien F, Superti-Furga G.

Cancer Res. 2012 Oct 1;72(19):4890-5. doi: 10.1158/0008-5472.CAN-12-1276. Epub 2012 Sep 21. Review.

Supplemental Content

Support Center